On October 14, 2026, ALX Oncology Holdings Inc. entered into privately-negotiated exchange agreements with certain stockholders to surrender an aggregate of 13,353,384 shares of common stock. In return, the company issued pre-funded warrants to purchase an equivalent number of shares. The transaction settled on October 15, 2026, and was conducted under a registration exemption. Key participants included funds affiliated with Blackstone Annex Master Fund L.P., RA Capital Healthcare Fund, L.P., and venBio Global Strategic Fund, L.P. ALX Oncology Holdings Inc. operates in the biotechnology industry, focusing on the development of cancer treatments.
